Cargando…
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
Biosimilars have been available in the USA for over a decade, and in Europe for almost two decades. In that time, biosimilars have become established in the treatment landscape for a wide range of diseases, facilitating patient access and affordability of healthcare. However, patients can still stru...
Autores principales: | Cohen, Hillel P., Turner, Matthew, McCabe, Dorothy, Woollett, Gillian R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432323/ https://www.ncbi.nlm.nih.gov/pubmed/37542600 http://dx.doi.org/10.1007/s40259-023-00619-0 |
Ejemplares similares
-
The Importance of Countering Biosimilar Disparagement and Misinformation
por: Cohen, Hillel P., et al.
Publicado: (2020) -
An Efficient Development Paradigm for Biosimilars
por: Webster, Christopher J., et al.
Publicado: (2019) -
A ‘Global Reference’ Comparator for Biosimilar Development
por: Webster, Christopher J., et al.
Publicado: (2017) -
The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders
por: Grampp, Gustavo, et al.
Publicado: (2015) -
Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?
por: George, Kelly, et al.
Publicado: (2019)